• Bioxyne enters emerging medicinal cannabis markets of Costa Rica and Panama
• Secures manufacturing and supply agreement with Remidose LATAM SRL
• Agreement includes minimum order commitments worth over A$1 million in potential annual revenue

Bioxyne Limited (ASX: BXN), through its wholly owned subsidiary Breathe Life Sciences (BLS), has entered into a Manufacturing Agreement with Remidose LATAM SRL, a Costa Rican entity affiliated with Canadian medicinal cannabis company Remidose Aerosols Inc. Under the agreement, BLS will manufacture pharmaceutical-grade THC pastille products for supply into the emerging medicinal cannabis markets of Costa Rica and Panama. This marks Bioxyne's first entry into the Central American medicinal cannabis market, with potential for growth in South America. The agreement leverages BLS's position as a leading Australian GMP manufacturer of pharmaceutical-grade cannabis pastilles. Remidose selected BLS for its reliability and consistency in producing high-quality THC pastilles. The Costa Rican and Panamanian medicinal cannabis markets are in early stages of development, with pastille formats expected to play a significant role alongside other non-flower dosage forms. The agreement includes minimum order commitments that could generate over A$1 million in potential annual revenue once TGA export approvals and in-market product registrations are secured.

The agreement with Remidose LATAM SRL could generate over A$1 million in potential annual revenue once regulatory approvals are obtained.

The partnership with Remidose LATAM SRL represents a key step in Bioxyne's growth trajectory as the company continues to scale globally. It aligns with Bioxyne's 'people, purpose, profits' ethos, delivering a strategic foothold in underserved markets and reinforcing the company's role in redefining medicine across borders.